Curated News
By: NewsRamp Editorial Staff
May 15, 2025
Nutriband Expands Market Presence Through Strategic Partnerships with Charlotte FC and Kindeva Drug Delivery
TLDR
- Nutriband (NASDAQ: NTRB) expands market presence and capabilities through strategic partnerships, aiming to lead in transdermal drug delivery solutions.
- Nutriband collaborates with Charlotte FC and Kindeva Drug Delivery to develop proprietary technology and abuse-deterrent products for chronic pain management.
- Nutriband's partnerships aim to prevent drug abuse, diversify revenue streams, and improve transdermal drug delivery solutions for a better health and wellness industry.
- Nutriband introduces innovative AI Tape and AVERSA(TM) technology to address chronic pain with abuse-deterrent patches, enhancing drug delivery solutions for better patient outcomes.
Impact - Why it Matters
This news matters as Nutriband's partnerships signify a significant step towards diversifying revenue streams and establishing itself as a key player in the transdermal pharmaceutical products market. The collaboration with Kindeva Drug Delivery to develop Aversa(TM) Fentanyl highlights the company's commitment to innovation in addressing chronic pain management.
Summary
Nutriband (NASDAQ: NTRB) is expanding its market presence and manufacturing capabilities through strategic partnerships with Charlotte FC and Kindeva Drug Delivery. The company aims to reinforce its position as a leader in transdermal drug delivery solutions by collaborating with established brands in the health and wellness industry.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Nutriband Expands Market Presence Through Strategic Partnerships with Charlotte FC and Kindeva Drug Delivery
